Sharon Bio-Medicine has now informed that the board of directors at its meeting held on January 21, 2013, has resolved to convene an extra-ordinary general meeting to be held on February 16, 2013, for the approval of the shareholders on the said rollover of the existing FCCBs.
The above information is a part of company’s filings submitted to BSE.